drugset / Trial / NCT04255238

A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone

NCT04255238

Phase 3 Unknown 468 enrolled LG Chem
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of dual add-on therapy with Gemigliptin 50 mg and Dapagliflozin 10 mg added to Metformin compared to add-on therapy with Gemigliptin 50 mg in combination with Metformin or Dapagliflozin 10 mg in combination with Metformin in patients with type 2 diabetes mellitus who have inadequate glycemic control on metformin alone

Timeline

Start
2020-06-30
Primary completion
2022-05-30
Completion
2022-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg
Subject Gemigliptin Small molecule 50 mg